Apolipoprotein ɛ4 allele (APOEɛ4) is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD), but inconsistencies have arisen in studies with Hispanics. The objective of this study was to explore APOEɛ4 expression and cognitive function in a sample of Panamanian older adults, including healthy controls, mild cognitive impairment, and AD. Participants with at least one copy of APOEɛ4 had a significantly lower performance in global cognition, verbal memory, executive functions, visuospatial abilities, regardless of diagnosis. The present study contributes to the understanding of the association of APOEɛ4 and impairment in specific cognitive domains in elderly Hispanics.
Alzheimer Association (2019) 2019 Alzheimer’s disease facts and figures. Alzheimers Dement15, 321–387.
2.
BangenKJ, BeiserA, Delano-WoodL, NationDA, LamarM, LibonDJ, BondiMW, SeshadriS, WolfPA, AuR (2013) APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis22, 1361–1369.
3.
KangJH, LogroscinoG, De VivoI, HunterD, GrodsteinF (2005) Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol Aging26, 475–484.
4.
TaiLM, ThomasR, MarottoliFM, KosterKP, KanekiyoT, MorrisAWJ, BuG (2016) The role of APOE in cerebrovascular dysfunction. Acta Neuropathol131, 709–723.
5.
FarrerLA, CupplesLA, HainesJL, HymanB, KukullW a, MayeuxR, MyersRH, Pericak-VanceM a, RischN, van DuijnCM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA278, 1349–1356.
6.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
7.
VerghesePB, CastellanoJM, HoltzmanDM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol10, 241–252.
8.
TangMX, MaestreG, TsaiWY, LiuXH, FengL, ChungWY, ChunM, SchofieldP, SternY, TyckoB, MayeuxR (1996) Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet58, 574–584.
9.
HaanMN, MungasDM, GonzalezHM, OrtizTA, AcharyaA, JagustWJ (2003) Prevalence of dementia in older latinos: The influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc51, 169–177.
10.
GurejeO, OgunniyiA, BaiyewuO, PriceB, UnverzagtFW, EvansRM, Smith-GambleV, LaneKA, GaoS, HallKS, HendrieHC, MurrellJR (2006) APOE epsilon4 is not associated with Alzheimer’s disease in elderly Nigerians. Ann Neurol59, 182–185.
11.
JacquierM, ArangoD, VillarealE, TorresO, SerranoML, CrutsM, MontañesP, CanoC, RodriguezMN, SerneelsS, Van BroeckhovenC (2001) APOE ɛ4 and Alzheimer’s disease: Positive association in a Colombian clinical series and review of the Latin-American studies. Arq Neuropsiquiatr59, 11–17.
12.
QuirogaP, CalvoC, AlbalaC, UrquidiJ, SantosJL, PérezH, KlaassenG (1999) Apolipoprotein E polymorphism in elderly Chilean people with Alzheimer’s disease. Neuroepidemiology18, 48–52.
13.
MorelliL, LeoniJ, CastanoEM, MangoneCA, LambiertoA (1996) Apolipoprotein E polymorphism and late onset Alzheimer’s disease in Argentina. J Neurol Neurosurg Psychiatry61, 426–427.
14.
VillarrealAE,
GrajalesS,
O’BryantSE,
EdwardsM,
LópezL,
MontalvánA,
BrittonGB, Panama Aging Research Initiative (2016). Characterization of Alzheimer’s disease and mild cognitive impairment in older adults in Panama. Journal of Alzheimer’s Disease, 54, 897–901. doi: 10.3233/JAD-160402. PMID: 27567849.
SevushS, PeruyeraG, CrawfordF, MullanM (2000) Apolipoprotein-E epsilon 4 allele frequency and conferred risk for Cuban Americans with Alzheimer’s disease. Am J Geriatr Psychiatry8, 254–256.
17.
OlichneyJM, HansenLA, HofstetterCR, LeeJH, KatzmanR, ThalLJ (2000) Association between severe cerebral amyloid angiopathy and cerebrovascular lesions in Alzheimer disease is not a spurious one attributable to apolipoprotein E4. Arch Neurol57, 869–874.
18.
TaiLM, MehraS, SheteV, EstusS, RebeckGW, BuG, LaDuMJ (2014) Soluble apoE/Aβ complex: Mechanism and therapeutic target for APOE4-induced AD risk. Mol Neurodegener9, 2–.
19.
KeableA, FennaK, YuenHM, JohnstonDA, SmythNR, SmithC, SalmanRAS, SamarasekeraN, NicollJAR, AttemsJ, KalariaRN, WellerRO, CarareRO (2016) Deposition of amyloid β in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. Biochim Biophys Acta1862, 1037–1046.
20.
PoirierJ, DelisleMC, QuirionR, AubertI, FarlowM, LahiriD, HuiS, BertrandP, NalbantogluJ, GilfixBM, GauthierS (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A92, 12260–12264.
21.
RawleMJ, DavisD, BendayanR, WongA, KuhD, RichardsM (2018) Apolipoprotein-E (Apoe) E4 and cognitive decline over the adult life course. Transl Psychiatry8, 18–.
22.
LiW, QiuQ, SunL, LiX, XiaoS (2019) Short-term adverse effects of the apolipoprotein E ɛ4 allele over language function and executive function in healthy older adults. Neuropsychiatr Dis Treat15, 1855–1861.
23.
RabinLA, SmartCM, CranePK, AmariglioRE, BermanLM, BoadaM, BuckleyRF, ChételatG, DuboisB, EllisKA, GiffordKA, JeffersonAL, JessenF, KatzMJ, LiptonRB, LuckT, MaruffP, MielkeMM, MolinuevoJL, NaeemF, PerrotinA, PetersenRC, RamiL, ReisbergB, RentzDM, Riedel-HellerSG, RisacherSL, RodriguezO, SachdevPS, SaykinAJ, SlavinMJ, SnitzBE, SperlingRA, TandetnikC, Van Der FlierWM, WagnerM, WolfsgruberS, SikkesSAM (2015) Subjective cognitive decline in older adults: An overview of self-report measures used across 19 international research studies.S. J Alzheimers Dis48(Suppl 1), 63–86.
24.
LuoX, JiaerkenY, YuX, HuangP, QiuT, JiaY, SunJ, ZhouJ, ZhangM, For The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2017) Affect of APOE on information processing speed in non-demented elderly population: A preliminary structural MRI study. Brain Imaging Behav11, 977–985.
WangX, ZhuM, HjorthE, Cortés-ToroV, EyjolfsdottirH, GraffC, NennesmoI, PalmbladJ, EriksdotterM, SambamurtiK, FitzgeraldJM, SerhanCN, GranholmAC, SchultzbergM (2015) Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement11, 40–50.
27.
MarioniRE, CampbellA, ScotlandG, HaywardC, PorteousDJ, DearyIJ (2016) Differential effects of the APOE e4 allele on different domains of cognitive ability across the life-course. Eur J Hum Genet24, 919–923.
28.
WisdomNM, CallahanJL, HawkinsKA (2011) The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis. Neurobiol Aging32, 63–74.
29.
SunS, FuJ, ChenJ, PangW, HuR, LiH, TanL, JiangY (2015) ApoE type 4 allele affects cognitive function of aged population in Tianjin City, China. Am J Alzheimers Dis Other Demen30, 503–507.
30.
LimYY, EllisKA, PietrzakRH, AmesD, DarbyD, HarringtonK, MartinsRN, MastersCL, RoweC, SavageG, SzoekeC, VillemagneVL, MaruffP (2012) Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology79, 1645–1652.
31.
PiskunowiczMT, LinkowskaK, GołotaS, GrzybowskiT, Kędziora-KornatowskaK, BorkowskaA (2018) The association of apolipoprotein E gene polymorphism with cognitive performance in nondemented Polish adults aged 55 to 75. Int J Aging Hum Dev87, 124–140.
32.
VillarealAE,
Pérez-LaoAR,
OviedoDC,
GrajalesS,
CarreiraMB,
BrittonGB, the Panama Aging Research Initiative Group (2019) The Panama aging research initiative longitudinal study. MEDICC Rev21, 54–58.
33.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
36.
DasHK, McPhersonJ, BrunsGAP, KarathanasisSK, BreslowJL (1985) Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem260, 6240–6247.
37.
KochW, EhrenhaftA, GriesserK, PfeuferA, MüllerJ, SchömigA, KastratiA (2002) TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin Chem Lab Med40, 1123–1131.
38.
TschanzJT, CorcoranCD, SchwartzS, TreiberK, GreenRC, NortonMC, MielkeMM, PiercyK, SteinbergM, RabinsP V, LeoutsakosJ-M, Welsh-BohmerKA, BreitnerJCS, LyketsosCG (2011) Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: The Cache County Dementia Progression study. Am J Geriatr Psychiatry19, 532–542.
39.
KanayaK, AbeS, SakaiM, FujiiH, IwamotoT (2010) Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: Relating to changes attributable to differences in apolipoprotein E phenotype. Geriatr Gerontol Int10, 25–31.
40.
SmallBJ, RosnickCB, FratiglioniL, BackmanL (2004) Apolipoprotein E and cognitive performance: A meta-analysis. Psychol Aging19, 592–600.
41.
KobyleckiC, HaenseC, HarrisJM, StopfordCL, SegobinSH, JonesM, RichardsonAMT, GerhardA, Anton-RodriguezJ, ThompsonJC, HerholzK, SnowdenJS (2017) Functional neuroanatomical associations of working memory in early-onset Alzheimer’s disease. Int J Geriatr Psychiatry33, 176–184.
42.
Quintino-SantosS, DinizBS, FirmoJOA, MoriguchiEH, Lima-CostaMF, Castro-CostaE (2015) APOE epsilon4 allele is associated with worse performance in memory dimensions of the mini-mental state examination: The Bambui Cohort Study of Aging. Int J Geriatr Psychiatry30, 573–579.
43.
TuranaY, Suzy HandajaniY, WidjajaNT (2015) Association between APOE epsilon4 genotype and memory impairment in elderly with normal global cognitive assessment. Diagnostics (Basel)5, 615–623.
44.
CaselliRJ, LockeDEC, DueckAC, KnopmanDS, WoodruffBK, Hoffman-SnyderC, RademakersR, FleisherAS, ReimanEM (2014) The neuropsychology of normal aging and preclinical Alzheimer’s disease. Alzheimers Dement10, 84–92.
45.
LuckT, ThenFS, LuppaM, SchroeterML, ArélinK, BurkhardtR, ThieryJ, LöfflerM, VillringerA, Riedel-HellerSG (2014) Association of the apolipoprotein E genotype with memory performance and executive functioning in cognitively intact elderly. Neuropsychology29, 382–387.
46.
FioccoAJ, PoirierJ, JooberR, NairNP V, LupienSJ (2008) Acute and long-term associations between ApoE genetic polymorphism, cortisol levels, and declarative memory performance in older adults. Psychoneuroendocrinology33, 625–633.
47.
BunceD, BielakAA, AnsteyKJ, CherbuinN, BatterhamPJ, EastealS (2014) APOE genotype and cognitive change in young, middle-aged, and older adults living in the community. J Gerontol A Biol Sci Med Sci69, 379–86.
48.
CarlsonMC, XueQL, ZhouJ, FriedLP (2009) Executive decline and dysfunction precedes declines in memory: The Women’s Health and Aging Study II. J Gerontol A Biol Sci Med Sci64, 110–117.
49.
ClarkLR, SchiehserDM, WeissbergerGH, SalmonDP, DelisDC, BondiMW (2012) Specific measures of executive function predict cognitive decline in older adults. J Int Neuropsychol Soc18, 118–127.
50.
KirovaA-M, BaysRB, LagalwarS (2015) Working memory and executive function decline across normal aging, mild cognitive impairment, and Alzheimer’s disease. Biomed Res Int2015, 1–9.
51.
SchroeterML, SteinT, MaslowskiN, NeumannJ (2009) Neural correlates of Alzheimer’s disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients. Neuroimage47, 1196–1206.
52.
HoneaRA, VidoniE, HarshaA, BurnsJM (2009) Impact of APOE on the healthy aging brain: A voxel-based MRI and DTI study. J Alzheimers Dis18, 553–564.
53.
GuLH, ChenJ, GaoLJ, ShuH, WangZ, LiuD, YanYN, LiSJ, ZhangZJ (2017) The effect of apolipoprotein E ɛ4 (APOE ɛ4) on visuospatial working memory in healthy elderly and amnestic mild cognitive impairment patients: An event-related potentials study. Front Aging Neurosci9, 145–.
54.
DikMG, JonkerC, ComijsHC, BouterLM, TwiskJW, van KampGJ, DeegDJ (2001) Memory complaints and APOE-epsilon4 accelerate cognitive decline in cognitively normal elderly. Neurology57, 2217–2222.
55.
TombaughTN (2004) Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol19, 203–214.
56.
MonschAU, BondiMW, ButtersN, SalmonDP, KatzmanR, ThalLJ (1992) Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type. Arch Neurol49, 1253–1258.
57.
AuriacombeS, LechevallierN, AmievaH, HarstonS, RaouxN, DartiguesJ-F (2006) A longitudinal study of quantitative and qualitative features of category verbal fluency in incident Alzheimer’s disease subjects: Results from the PAQUID study. Dement Geriatr Cogn Disord21, 260–266.
58.
HantkeN, NielsonKA, WoodardJL, BretingLMG, ButtsA, SeidenbergM, Carson SmithJ, DurgerianS, LancasterM, MatthewsM, SugarmanMA, RaoSM (2013) Comparison of semantic and episodic memory BOLD fMRI activation in predicting cognitive decline in older adults. J Int Neuropsychol Soc19, 11–21.
59.
RosenVM, SunderlandT, LevyJ, HarwellA, McGeeL, HammondC, BhupaliD, PutnamK, BergesonJ, LefkowitzC (2005) Apolipoprotein E and category fluency: Evidence for reduced semantic access in healthy normal controls at risk for developing Alzheimer’s disease. Neuropsychologia43, 647–658.
60.
RosenVM, BergesonJL, PutnamK, HarwellA, SunderlandT (2002) Working memory and apolipoprotein E: What’s the connection?Neuropsychologia40, 2226–2233.
61.
GreenwoodPM, LambertC, SunderlandT, ParasuramanR (2005) Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: Results From the National Institute of Mental Health’s BIOCARD study. Neuropsychology19, 199–211.
62.
MichaudTL, SuD, SiahpushM, MurmanDL (2017) The risk of incident mild cognitive impairment and progression to dementia considering mild cognitive impairment subtypes. Dement Geriatr Cogn Dis Extra7, 15–29.
